Sensei Biotherapeutics, Inc. Common Stock (SNSE) Stock Price

SNSEStock
$34.71+359.97%52W
Market Cap$46.58M
P/E
PEG Ratio
Div yield
Beta-0.31

SNSE Share Price Chart

Favorite Metrics

Price vs S&P 500 (26W)20.98%
Price vs S&P 500 (4W)16.10%
VGM Score84.58

SNSE Earnings Surprise History

Q2 25-3.91est. -5.00
Q3 25-3.62est. -4.11
Q4 25-3.74est. -4.81
Q1 26-131.45est. -0.62

SNSE Analyst Recommendations

Mar 2026
Apr 2026
May 2026
Jun 2026
2.17
2.17
4.13
4.20

Industry Peers — Pharmaceuticals(571)

SymbolValue ScoreGrowth ScoreMomentum ScorePrice
SNSESensei Biotherapeutics, Inc. Common Stock
A$34.71
LLYEli Lilly & Co.DBB$1233.66
JNJJohnson & JohnsonDCB$273.14
ABBVABBVIE INC.DCB$265.79
MRKMerck & Co., Inc.DCA$156.45
NVSNovartis AGCCC$159.98
AZNAstraZeneca PLCCBC$169.66
NVONovo-Nordisk A/SBCC$48.66
ABTAbbott LaboratoriesCCB$116.13
PFEPfizer Inc.CDC$28.57
VRTXVertex Pharmaceuticals IncDCB$552.85

About Sensei Biotherapeutics, Inc. Common Stock

Sensei Biotherapeutics is an immuno-oncology company developing next-generation cancer therapeutics through its TMAb (Tumor Microenvironment Activated Biologics) platform, which targets immunosuppressive and immunostimulatory signals within tumors. The company has four clinical-stage candidates in development: SNS-101 (VISTA), SNS-102 (VSIG4), SNS-103 (ENTPDase/CD39), and SNS-201 (VISTAxCD28). This targeted approach aims to improve outcomes for cancer patients by modulating the tumor microenvironment.